You are here

ASCO 2022

Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

BioSpace

Flag link:

The mystery of Jemperli’s rectal cancer breakthrough

The mystery of Jemperli’s rectal cancer breakthrough

EP Vantage

Flag link:

Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

BioSpace

clinical trials

Flag link:

CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

BioSpace

Jazz Pharmaceuticals

Flag link:

Merck Predicts Over 80 Potential Oncology Approvals Through 2028

Merck Predicts Over 80 Potential Oncology Approvals Through 2028

BioSpace

Flag link:

Roche keeps the faith in new cancer immunotherapy despite trial setbacks

Roche keeps the faith in new cancer immunotherapy despite trial setbacks

BioPharma Dive

clinical trials

Flag link:

ASCO 2022 – the spirit of Rova-T struggles to live on

ASCO 2022 – the spirit of Rova-T struggles to live on

EP Vantage

Harpoon Therapeutics

Boehringer Ingelheim

Flag link:

ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?

ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?

Fierce Biotech

NRG1 fusion-positive cancer

Flag link:

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

Pharmaforum

antibody-drug conjugate

Bristol Myers Squibb

Flag link:

Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

Pfizer's Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

BioSpace

HER2-negative breast cancer

Flag link:

ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says

ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says

Fierce Biotech

Mirati Therapeutics

Flag link:

#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets

#ASCO2022 roundup: CG Oncology builds on head-turning combo data; EQRx doesn’t have a way into US markets

Endpoints

Flag link:

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients

BioSpace

clinical trials

Flag link:

ASCO 2022 – Carvykti casts a long shadow

ASCO 2022 – Carvykti casts a long shadow

EP Vantage

Multiple Myeloma

Flag link:

ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance

ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance

Fierce Pharma

Bristol Myers Squibb

Flag link:

ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance

ASCO: Clovis CEO defends Rubraca's ovarian cancer win as FDA wants more assurance

Fierce Pharma

Flag link:

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Pharmaforum

bispecific antibodies

relapsed or refractory multiple myeloma

Flag link:

ASCO22: Enhertu aces key HER2-low test in breast cancer

ASCO22: Enhertu aces key HER2-low test in breast cancer

Pharmaforum

HER2-low breast cancer

Flag link:

ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in prostate cancer

ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in prostate cancer

Fierce Biotech

cancer vaccines

pancreatic cancer

Flag link:

ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt

ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt

Fierce Pharma

Gilead Sciences

Flag link:

Pages